Adocia S.A. (ADOCY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Adocia S.A. (ADOCY) with AI Score 56/100 (Hold). Adocia S. A. is a clinical-stage biotechnology company focused on developing innovative formulations of therapeutic proteins and peptides for diabetes and metabolic diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Adocia S.A. (ADOCY) Healthcare & Pipeline Overview
Adocia S.A., a French clinical-stage biotech, leverages its BioChaperone platform to develop improved formulations of approved therapeutic proteins for diabetes and metabolic disorders. With a strategic alliance with Tonghua Dongbao, Adocia targets the Chinese and Asian markets, facing competition from established pharmaceutical companies and other biotech firms.
Investment Thesis
Adocia S.A. presents a high-risk, high-reward investment opportunity. The company's BioChaperone technology has the potential to create differentiated insulin products with improved pharmacokinetic profiles, addressing unmet needs in diabetes management. The partnership with Tonghua Dongbao offers access to the Chinese market, a significant growth driver. However, Adocia's negative profit margin of -84.3% and gross margin of -77.5% highlight the financial challenges. Success hinges on positive clinical trial outcomes and successful commercialization, making it a speculative investment with potential for substantial returns if key milestones are achieved.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.17 billion reflects the company's early stage and potential for growth in the biotechnology sector.
- Negative P/E ratio of -9.42 indicates that the company is currently not profitable, common for clinical-stage biotech firms.
- Profit margin of -84.3% highlights the significant R&D expenses associated with drug development and clinical trials.
- Gross margin of -77.5% suggests that the cost of goods sold exceeds revenue, typical during the development phase.
- Beta of 0.86 indicates that the stock is less volatile than the overall market, potentially offering some downside protection.
Competitors & Peers
Strengths
- Proprietary BioChaperone technology platform.
- Strategic alliance with Tonghua Dongbao.
- Focus on reformulating approved drugs.
- Clinical-stage pipeline with multiple product candidates.
Weaknesses
- Negative profit and gross margins.
- Reliance on partnerships for commercialization.
- High R&D expenses.
- Limited product revenue.
Catalysts
- Upcoming: Clinical trial results for BioChaperone Lispro U100 and U200 will provide key data on efficacy and safety.
- Ongoing: Strategic alliance with Tonghua Dongbao for development and commercialization in China.
- Upcoming: Regulatory submissions for new product candidates in key markets.
- Ongoing: Expansion of the clinical pipeline with new formulations and therapeutic targets.
- Ongoing: Potential for out-licensing agreements and partnerships with other pharmaceutical companies.
Risks
- Potential: Clinical trial failures could significantly impact the company's pipeline and valuation.
- Ongoing: Competition from established pharmaceutical companies in the diabetes market.
- Potential: Regulatory hurdles and delays in obtaining approval for new products.
- Ongoing: Dependence on partnerships for commercialization and distribution.
- Ongoing: Negative profit and gross margins raise concerns about financial sustainability.
Growth Opportunities
- Expansion in the Chinese Market: Adocia's strategic alliance with Tonghua Dongbao provides a significant growth opportunity in China, a market with a large and growing population of individuals with diabetes. Successful development and commercialization of BioChaperone Lispro and BioChaperone Combo in China could generate substantial revenue streams for Adocia. The timeline for this growth opportunity is dependent on regulatory approvals and market penetration, potentially unfolding over the next 3-5 years.
- Advancement of the Clinical Pipeline: Adocia's clinical pipeline, including BioChaperone Lispro U100/U200 and BioChaperone Combo, represents a key growth driver. Positive clinical trial results and subsequent regulatory approvals could lead to the launch of new and improved insulin products. The timeline for this growth opportunity depends on the progress of clinical trials, with potential product launches within the next 2-4 years.
- Development of Bi-hormonal and Multi-hormonal Products: Adocia's preclinical pipeline includes bi-hormonal and multi-hormonal products targeting obesity, such as BioChaperone GluExe, PramExe, and BioChaperone PramGluExe. These products address a significant unmet need in the growing obesity market. The timeline for this growth opportunity is longer-term, with potential clinical trials and product launches in 5+ years.
- Out-licensing and Partnerships: Adocia can pursue out-licensing agreements and partnerships with other pharmaceutical companies to further develop and commercialize its products. These partnerships can provide Adocia with additional funding and expertise, accelerating the development and commercialization process. The timeline for this growth opportunity is variable, depending on the specific partnerships and agreements.
- Expansion into New Therapeutic Areas: While currently focused on diabetes and metabolic diseases, Adocia's BioChaperone technology could be applied to other therapeutic areas, such as cardiovascular disease or neurology. Expanding into new therapeutic areas would diversify Adocia's product pipeline and reduce its reliance on the diabetes market. The timeline for this growth opportunity is longer-term, requiring significant R&D investment and strategic planning.
Opportunities
- Expansion in the Chinese market.
- Advancement of the clinical pipeline.
- Development of bi-hormonal and multi-hormonal products.
- Out-licensing and partnerships.
Threats
- Competition from established pharmaceutical companies.
- Clinical trial failures.
- Regulatory hurdles.
- Patent expiration.
Competitive Advantages
- Proprietary BioChaperone technology platform provides a unique approach to improving existing drugs.
- Patent protection on its formulations and technologies creates a barrier to entry.
- Strategic alliance with Tonghua Dongbao provides access to the Chinese market.
- Focus on reformulating approved drugs potentially reduces development timelines and risks.
About ADOCY
Adocia S.A., founded in 2005 and headquartered in Lyon, France, is a biotechnology company specializing in the research and development of innovative formulations for the treatment of diabetes and other metabolic diseases. The company's core technology is its proprietary BioChaperone platform, designed to enhance the performance and safety profiles of existing therapeutic proteins and peptides. Adocia's approach focuses on reformulating already approved drugs, potentially reducing development timelines and risks compared to developing novel molecules. The company's clinical pipeline features several insulin formulations, including BioChaperone Lispro U100 and U200, ultra-rapid insulin formulations based on insulin lispro. Other clinical-stage products include BioChaperone Combo, a combination of insulin glargine and rapid-acting insulin lispro, and BioChaperone LisPram, combining prandial insulin with pramlintide. Adocia is also developing BioChaperone Glucagon, an aqueous formulation of human glucagon for hypoglycemia treatment, and M1Pram, a metabolite of insulin glargine and pramlintide. The preclinical pipeline includes bi-hormonal and multi-hormonal products targeting obesity, such as BioChaperone GluExe, PramExe, and BioChaperone PramGluExe. Adocia has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. This partnership provides Adocia with access to a large and rapidly growing market for diabetes treatments.
What They Do
- Researches and develops formulations of therapeutic proteins and peptides.
- Focuses on treatments for diabetes and other metabolic diseases.
- Utilizes its proprietary BioChaperone technological platform to optimize therapeutic proteins.
- Develops ultra-rapid insulin formulations based on rapid insulin lispro.
- Creates combinations of insulin glargine and rapid-acting insulin lispro.
- Develops aqueous formulations of human glucagon for the treatment of hypoglycemia.
Business Model
- Develops and patents improved formulations of existing therapeutic proteins.
- Conducts clinical trials to demonstrate the safety and efficacy of its products.
- Seeks regulatory approval for its products from agencies like the FDA and EMA.
- Partners with pharmaceutical companies for commercialization and distribution, such as Tonghua Dongbao.
Industry Context
Adocia operates in the competitive biotechnology industry, specifically targeting the diabetes and metabolic disease market. This market is driven by the increasing prevalence of diabetes globally, creating a significant demand for improved treatments. The competitive landscape includes established pharmaceutical companies like Novo Nordisk and Eli Lilly, as well as other biotech firms developing novel diabetes therapies. Adocia's BioChaperone technology aims to differentiate its products by improving the performance of existing insulin formulations.
Key Customers
- Patients with diabetes who require insulin therapy.
- Healthcare providers who prescribe insulin and other diabetes medications.
- Pharmaceutical companies that license or partner with Adocia to commercialize its products.
Financials
Chart & Info
Adocia S.A. (ADOCY) stock price: Price data unavailable
Latest News
No recent news available for ADOCY.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ADOCY.
Price Targets
Wall Street price target analysis for ADOCY.
MoonshotScore
What does this score mean?
The MoonshotScore rates ADOCY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Olivier Soula
Chief Executive Officer
Olivier Soula serves as the Chief Executive Officer of Adocia S.A. His background includes extensive experience in the pharmaceutical and biotechnology industries. Specific details regarding his educational background and previous roles are not available. As CEO, he is responsible for leading the company's strategic direction and overseeing its operations.
Track Record: Under Olivier Soula's leadership, Adocia has focused on advancing its clinical pipeline and securing partnerships, including the strategic alliance with Tonghua Dongbao. Key milestones include the progress of clinical trials for BioChaperone Lispro and BioChaperone Combo. However, specific details regarding his individual achievements and impact on the company's financial performance are not available.
Adocia S.A. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. ADOCY is an ADR, meaning it allows U.S. investors to invest in Adocia S.A. without the complexities of cross-border transactions. The ADR is denominated in U.S. dollars, and dividends are paid in U.S. dollars.
- Home Market Ticker: Euronext Paris, France
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: ADOC
ADOCY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulation and transparency compared to listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in ADOCY.
- Low trading volume and wide bid-ask spread can lead to price volatility and illiquidity.
- The OTC Other tier has less regulatory oversight, increasing the risk of fraud or manipulation.
- Currency risk due to the company being based in France.
- Potential for delisting from the OTC market.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's competitive landscape and market position.
- Understand the company's business model and revenue streams.
- Evaluate the company's intellectual property and patent protection.
- Consult with a financial advisor to assess the risks and potential rewards of investing in ADOCY.
- Check for any legal or regulatory issues involving the company.
- The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd.
- Adocia S.A. was incorporated in 2005 and has been operating for several years.
- The company has a clinical-stage pipeline with multiple product candidates.
Common Questions About ADOCY
What does Adocia S.A. do?
Adocia S.A. is a clinical-stage biotechnology company that specializes in developing innovative formulations of already approved therapeutic proteins and peptides, primarily focused on improving treatments for diabetes and metabolic diseases. Their core technology, the BioChaperone platform, aims to enhance the efficacy, safety, and patient experience of existing drugs. The company's pipeline includes ultra-rapid insulin formulations and combinations of different diabetes medications, seeking to address unmet needs in diabetes management and potentially expand into obesity treatments.
What do analysts say about ADOCY stock?
AI analysis is currently pending for ADOCY. Generally, clinical-stage biotechnology companies like Adocia are evaluated based on the potential of their drug pipeline, clinical trial results, and partnerships. Key valuation metrics include the potential market size for their products and the likelihood of regulatory approval. Investing in such companies involves significant risk due to the uncertainty of drug development and commercialization.
What are the main risks for ADOCY?
The main risks for Adocia S.A. include the inherent challenges of drug development, such as clinical trial failures and regulatory hurdles. Competition from established pharmaceutical companies with greater resources and market share poses a significant threat. Financial risks include the company's negative profit and gross margins, reliance on partnerships for commercialization, and the need for ongoing funding to support its R&D activities. Additionally, as an ADR, ADOCY is subject to currency risk.
What are the key factors to evaluate for ADOCY?
Adocia S.A. (ADOCY) currently holds an AI score of 56/100, indicating moderate score. Key strength: Proprietary BioChaperone technology platform.. Primary risk to monitor: Potential: Clinical trial failures could significantly impact the company's pipeline and valuation.. This is not financial advice.
How frequently does ADOCY data refresh on this page?
ADOCY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ADOCY's recent stock price performance?
Recent price movement in Adocia S.A. (ADOCY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary BioChaperone technology platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ADOCY overvalued or undervalued right now?
Determining whether Adocia S.A. (ADOCY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ADOCY?
Before investing in Adocia S.A. (ADOCY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for ADOCY, limiting the depth of analysis.
- OTC market data may be less reliable than data for listed companies.